Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 8/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931108 | 0.91 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10PARP1 | |
| SCHEMBL3041953 | 0.79 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10PARP1 | |
| SCHEMBL6493490 | 0.75 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL3568709 | 0.69 | GSK3B (0.48) | KDM4EALDH1A1POLB | |
| SCHEMBL3701968 | 0.67 | KDM4E (0.44) | KDM4EALDH1A1HPGDHSD17B10PARP1 | |
| SCHEMBL4487254 | 0.65 | KDM4E (0.41) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL20304594 | 0.65 | KDM4E (0.38) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL10824587 | 0.64 | ALDH1A1 (1.00) | KDM4EALDH1A1HPGDHSD17B10PARP1 | |
| SCHEMBL4587227 | 0.62 | KDM5B (0.35) | KDM4EALDH1A1HPGDKDM5B | |
| SCHEMBL9955876 | 0.62 | ALDH1A1 (0.44) | KDM4EALDH1A1HPGDHSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162443-B1 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| JP-2010189422-A | PHARMACEUTICAL COMPOSITION CONTAINING 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-a]PYRIMIDIN-5(1H)ONE DERIVATIVE | SANOFI-AVENTIS | 2010-09-02 | — | — | JP | disclosed |
| US-7781440-B2 | Use of substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20080269257-A1 | Use of Substituted 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-A] Pyrimidin-4-one and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-A] Pyrimidin-5(1H)one Derivatives | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
| US-7388005-B2 | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo [1,2-a]pyrimidin-5(1H)one derivatives for neurodegenerative disorders | SANOFI-AVENTIS (FR) | 2008-06-17 | — | — | US | disclosed |
| CN-1247586-C | Substituted 2-pyrimidinyl-6, 7,8, 9-tetrahydropyrimido [1, 2-A ] pyrimidin-4-one and 7-pyrimidinyl-2, 3-dihydroimidazo [1, 2-A ] pyrimidin-5 (1H) one derivatives for the treatment of neurodegenerative diseases | SANOFI AVENTIS SYNTHELABO (FR) | 2006-03-29 | — | — | CN | disclosed |
| EP-1430056-B1 | SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES FOR NEURODEGENERATIVE DISORDERS | SANOFI AVENTIS (FR) | 2005-10-26 | — | — | EP | disclosed |
| US-20040266793-A1 | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders | SANOFI (FR) | 2004-12-30 | — | — | US | disclosed |
| CN-1556810-A | Substituted 2-pyrimidinyl-6, 7,8, 9-tetrahydropyrimido [1, 2-A ] pyrimidin-4-one and 7-pyrimidinyl-2, 3-dihydroimidazo [1, 2-A ] pyrimidin-5 (1H) one derivatives for the treatment of neurodegenerative diseases | ����ɳŵ��-����������˾ | 2004-12-22 | — | — | CN | disclosed |
| EP-1348708-A1 | Heteroaryl substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-10-01 | — | — | EP | disclosed |
| EP-1340760-A1 | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003027115-A1 | SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES FOR NEURODEGENERATIVE DISORDERS | SANOFI-SYNTHELABO (FR) | 2003-04-03 | — | — | WO | disclosed |
| EP-1295884-A1 | 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269257-A1 | Use of Substituted 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-A] Pyrimidin-4-one and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-A] Pyrimidin-5(1H)one Derivatives | CDK5, PSEN2, PSEN1 | KDM4E 2488/4885ALDH1A1 1388/4885HPGD 2478/4885 |
| US-20040266793-A1 | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders | CDK5, GSK3A, GSK3B | KDM4E 2683/4885ALDH1A1 1916/4885HPGD 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.